Teva UK Limited Launches Dorzolamide/Timolol Ophthalmic Solution

CASTLEFORD, England, October 4, 2010 - We are pleased to announce the launch of Dorzolamide/Timolol 20mg/5mg per
ml ophthalmic solution.

It is indicated in the treatment of elevated intra-ocular pressure (IOP)
in patients with open-angle glaucoma or pseudo-exfoliative glaucoma when
topical beta-blocker monotherapy is not sufficient(1).

It is a generic version of Cosopt(R) from Merck Sharp & Dohme Limited and
is available immediately in the award-winning Teva 360 livery, which is
designed to aid patient safety, as Dorzolamide/Timolol 20mg/5mg per ml
Ophthalmic Solution 5ml in a single pack.

The Teva retail price for the product is GBP9.05.

Kim Innes, Commercial Director at Teva UK Limited said "We are pleased to
add this product to our ever-expanding product portfolio - the widest of any
UK generics supplier."

To find out more about Teva UK Limited, visit www.tevauk.com.

References:

1. Dorzolamide/Timolol Ophthalmic Solution Summary of Product
Characteristics

Notes to Editors:

About Teva UK Limited

Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers,
with a presence in the generics, branded respiratory and hospitals markets.
It has the widest range of any UK generic pharmaceutical company and markets
solid and liquid dose, injectable and respiratory medicines to healthcare
professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's largest generic
drug maker, with a global product portfolio of more than 1,250 molecules and
a direct presence in 59 countries.

Teva's branded businesses focus on neurological, respiratory and women's
health therapeutic areas as well as biologics. Teva's leading innovative
product, Copaxone(R), is the number one prescribed treatment for multiple
sclerosis. Teva employs over 40,000 people around the world and reached $13.9
billion in net sales in 2009.

For media enquiries, contact the Teva UK Limited Communications team on +44-(0)1977-628500, or email media.enquiries at tevauk.com.